- Home
- DOGZ vs KALA Comparison
DOGZ vs KALA Comparison
Compare DOGZ & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOGZ
- KALA
- Stock Information
- Founded
- DOGZ 2003
- KALA 2009
- Country
- DOGZ China
- KALA United States
- Employees
- DOGZ N/A
- KALA N/A
- Industry
- DOGZ Miscellaneous manufacturing industries
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- DOGZ Consumer Discretionary
- KALA Health Care
- Exchange
- DOGZ Nasdaq
- KALA Nasdaq
- Market Cap
- DOGZ N/A
- KALA 26.2M
- IPO Year
- DOGZ 2017
- KALA 2017
- Fundamental
- Price
- DOGZ $25.74
- KALA $3.72
- Analyst Decision
- DOGZ
- KALA Strong Buy
- Analyst Count
- DOGZ 0
- KALA 2
- Target Price
- DOGZ N/A
- KALA $13.50
- AVG Volume (30 Days)
- DOGZ 304.1K
- KALA 56.4K
- Earning Date
- DOGZ 06-06-2025
- KALA 05-14-2025
- Dividend Yield
- DOGZ N/A
- KALA N/A
- EPS Growth
- DOGZ N/A
- KALA N/A
- EPS
- DOGZ N/A
- KALA N/A
- Revenue
- DOGZ $20,258,926.00
- KALA N/A
- Revenue This Year
- DOGZ N/A
- KALA N/A
- Revenue Next Year
- DOGZ N/A
- KALA N/A
- P/E Ratio
- DOGZ N/A
- KALA N/A
- Revenue Growth
- DOGZ 46.16
- KALA N/A
- 52 Week Low
- DOGZ $9.61
- KALA $2.92
- 52 Week High
- DOGZ $58.50
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- DOGZ 72.08
- KALA 46.95
- Support Level
- DOGZ $21.01
- KALA $3.67
- Resistance Level
- DOGZ $24.30
- KALA $4.16
- Average True Range (ATR)
- DOGZ 1.80
- KALA 0.31
- MACD
- DOGZ 0.97
- KALA 0.08
- Stochastic Oscillator
- DOGZ 100.00
- KALA 53.89
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.